Comera Life Sciences Holdings (Comera Life Sciences Holdings) Cash-to-Debt : 10.28 (As of Sep. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Comera Life Sciences Holdings Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Comera Life Sciences Holdings's cash to debt ratio for the quarter that ended in Sep. 2023 was 10.28.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Comera Life Sciences Holdings could pay off its debt using the cash in hand for the quarter that ended in Sep. 2023.

The historical rank and industry rank for Comera Life Sciences Holdings's Cash-to-Debt or its related term are showing as below:

CMRA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.96 Med: 6.47 Max: 20.09
Current: 10.28

During the past 3 years, Comera Life Sciences Holdings's highest Cash to Debt Ratio was 20.09. The lowest was 0.96. And the median was 6.47.

CMRA's Cash-to-Debt is ranked better than
55.82% of 1478 companies
in the Biotechnology industry
Industry Median: 7.005 vs CMRA: 10.28

Comera Life Sciences Holdings Cash-to-Debt Historical Data

The historical data trend for Comera Life Sciences Holdings's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Comera Life Sciences Holdings Cash-to-Debt Chart

Comera Life Sciences Holdings Annual Data

Trend

Dec20

Dec21

Dec22

Cash-to-Debt

0.96

20.09

1.40

Comera Life Sciences Holdings Quarterly Data
	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Cash-to-Debt	Get a 7-Day Free Trial						7.27	1.40	5.66	2.14	10.28

Competitive Comparison of Comera Life Sciences Holdings's Cash-to-Debt

For the Biotechnology subindustry, Comera Life Sciences Holdings's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Comera Life Sciences Holdings's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Comera Life Sciences Holdings's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Comera Life Sciences Holdings's Cash-to-Debt falls into.

Comera Life Sciences Holdings Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Comera Life Sciences Holdings's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.447	/	(0.199	+	0.12)
	=	1.40

Comera Life Sciences Holdings's Cash to Debt Ratio for the quarter that ended in Sep. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1.768	/	(0.172	+	0)
	=	10.28

Comera Life Sciences Holdings (OTCPK:CMRA) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Comera Life Sciences Holdings Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Comera Life Sciences Holdings's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Comera Life Sciences Holdings (Comera Life Sciences Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Comera Life Sciences Holdings Inc (OTCPK:CMRA) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

12 Gill Street, Suite 4650, Woburn, MA, USA, 01801

Website

https://www.comeralifesciences.com

Comera Life Sciences Holdings Inc is a pre-clinical biotechnology company dedicated to promoting formulation science and technology to transform essential biologic medicines from intravenous to subcutaneous forms. Comera's internal portfolio of proprietary techniques known as the SQore platform is designed to potentially transform essential biologic medicines from intravenous (IV) to subcutaneous (SQ) forms, and optimize current versions of subcutaneous biologics, and produce biosimilar versions of existing subcutaneous products. It also collaborates with pharmaceutical and biotechnology companies, applying the SQore platform to the Company's partners' biologic medicines to deliver enhanced formulations that facilitate self-injectable care.

Executives

Michael Gerard Campbell	officer: Chief Financial Officer	C/O COMERA LIFE SCIENCES HOLDINGS, INC., 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Charles Cherington	10 percent owner	ONE BOW STREET, CAMBRIDGE MA 02138
David Soane	10 percent owner	C/O SOANE LABS, LLC, 380 NE 72ND TERRACE, MIAMI FL 33138
Robert Patrick Mahoney	officer: Chief Scientific Officer	12 GILL STREET, SUITE 4650, WOBURN MA 01801
Barbara K Finck	director	C/O PROTINE DESIGN LAB, 3858 JACKSON ST, SAN FRANCISCO CA 94118
Kirsten Flowers	director	C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
James Sherblom	director	12 GILL STREET, SUITE 4650, WOBURN MA 01801
Stuart A Randle	director	585 WEST 500 SOUTH, BOUNTIFUL UT 84010
Sullivan Edward Aloysius Jr.	director	12 GILL STREET, SUITE 4650, WOBURN MA 01801
Sirshendu Roopom Banerjee	director	12 GILL STREET, SUITE 4650, WOBURN MA 01801
Janice Mccourt	officer: Chief Business Officer	C/O COMERA LIFE SCIENCES HOLDINGS, INC., 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Jeffrey S. Hackman	director, officer: See Remarks	12 GILL STREET, SUITE 4650, WOBURN MA 01801
John D. Yee	director	12 GILL STREET, SUITE 4650, WOBURN MA 01801
Neal Muni	officer: See Remarks	12 GILL STREET, SUITE 4650, WOBURN MA 01801
Phoenix Venture Partners Lp	10 percent owner	36 DOCKSIDE CIRCLE, REDWOOD SHORES CA 94065